about
Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparumVaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infectionTLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humansExpression of Plasmodium falciparum erythrocyte membrane protein 1 in experimentally infected humansA long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaA plant-derived morphinan as a novel lead compound active against malaria liver stagesPrimaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunateGenistein-supplemented diet decreases malaria liver infection in mice and constitutes a potential prophylactic strategyTowards an in vitro model of Plasmodium hypnozoites suitable for drug discoveryMosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriersHumoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adultsThe dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in TanzaniaAdherence to chemoprophylaxis and Plasmodium falciparum anti-circumsporozoite seroconversion in a prospective cohort study of Dutch short-term travelers.The Plasmodium falciparum protein Pfg27 is dispensable for gametocyte and gamete production, but contributes to cell integrity during gametocytogenesisProtein export marks the early phase of gametocytogenesis of the human malaria parasite Plasmodium falciparumImmunity against HIV/AIDS, malaria, and tuberculosis during co-infections with neglected infectious diseases: recommendations for the European Union research priorities.Kinome-wide RNAi screen implicates at least 5 host hepatocyte kinases in Plasmodium sporozoite infection.Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.Low density parasitaemia, red blood cell polymorphisms and Plasmodium falciparum specific immune responses in a low endemic area in northern TanzaniaCaspase-12 and the inflammatory response to Yersinia pestis.The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malariaSubstantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission.Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs.Molecular Markers for Sensitive Detection of Plasmodium falciparum Asexual Stage Parasites and their Application in a Malaria Clinical Trial.The plasticity of Plasmodium falciparum gametocytaemia in relation to age in Burkina Faso.Bacterial superglue enables easy development of efficient virus-like particle based vaccines.Transgenic fluorescent Plasmodium cynomolgi liver stages enable live imaging and purification of Malaria hypnozoite-formsDNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.The effect of three-monthly albendazole treatment on malarial parasitemia and allergy: a household-based cluster-randomized, double-blind, placebo-controlled trial.Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria.A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmissionEvaluation of immunity against malaria using luciferase-expressing Plasmodium berghei parasites.Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes.New active drugs against liver stages of Plasmodium predicted by molecular topology.The impact of hotspot-targeted interventions on malaria transmission: study protocol for a cluster-randomized controlled trial.PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites.Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis.Sulfadoxine-pyrimethamine impairs Plasmodium falciparum gametocyte infectivity and Anopheles mosquito survival.
P50
Q24558561-5D635031-BB56-482E-A0C9-451C6FA5B547Q24628167-B161DD70-EFC3-4CD0-B450-C97DF4431AF7Q24678506-FA4C0A74-FDAC-4336-A243-4E1FAE6BA2A4Q24804115-EE079E2C-8481-4161-A1E6-A90C4F5F5DFCQ27644391-7222CC6C-725D-4839-B1E4-F9FBD3E6C05BQ28469086-2FCC83BC-03C5-4C2F-8EA5-1E1399628A60Q28469316-2162AE57-F8A8-4C4A-9364-803E52324578Q28473154-7EE8F65B-8A91-4E15-986A-C7B692046487Q28477602-7DF35C4C-C43B-4717-AD40-CB9EA59A4F46Q28482471-AF41362A-63FF-4533-9229-CF50F3D2FADCQ28727698-BC678ADF-237F-4777-9FBE-A414B3E44F0EQ28744581-587CDEA1-3246-46B1-BA14-F5FA0B331687Q29353761-30094E05-88A0-4002-9A42-6474CE5B78F3Q30041477-96E6222F-3224-4071-B284-4F070135F1B7Q30042317-C853C065-DE27-4D66-A6A1-E3514AF51A63Q33346254-30E86CFD-7123-4435-BCCB-5E74768142DDQ33383241-CA059D99-FDBB-408C-8D40-9516201A2DB6Q33394245-D868D31A-C12B-4BA0-A74B-92197F3FF398Q33449934-9F0115AC-CA34-45C5-B9E3-2E76A91FDC52Q33498939-B75EA030-4969-4CDD-A5F1-D769B8CE5584Q33512926-08F07EC9-6933-4CF9-9F5D-57786865664CQ33520254-565946C1-BA7F-4BED-8BF6-D8F0DC790D78Q33898575-29E6C5E9-BB1D-448D-BED6-A49F6E49F84BQ33901814-5F445C27-A8F0-47D6-82B7-B3813D53B4ECQ34488590-E529A21D-5350-47BB-9408-4D22A6647B6AQ34523734-6B64C1B5-7519-4BAA-AC05-73D275A06A9BQ34566578-0A89D5C4-0337-49F6-A769-FA529BC5D259Q34606356-C277579C-4080-4720-9E8A-63016323981CQ34634037-ADF585A4-F5AE-4388-A254-1CD2428650EEQ34873304-828099D8-24F4-429D-946D-1651C3E8381BQ35203887-F2A4666E-1A49-436C-B5AF-3EDD14DA7A11Q35598030-F5492BFF-4A27-4C75-BEDC-C8366D65FB7FQ35761522-24C7756D-7A7E-4306-92FC-E427DF4E34C5Q36267184-A1B5CF08-81DC-4F24-9E3C-12B9CD5A6613Q36399515-BAA248D5-FC09-4C9B-BD21-67FCA95D5987Q36538667-17AF934E-A3B8-4A5E-A141-7AB1D0350325Q36621479-F65264AA-52C7-43FC-A4F7-17DABC019183Q36887985-740C99F9-EE8D-4AD7-B586-214B369526F4Q36972498-D4B2FAFA-73BA-4A40-BDD1-9B226FA1DC41Q37097339-EA7BB54D-0424-48ED-B112-24E6C3273D12
P50
name
Robert Sauerwein
@en
Robert Sauerwein
@es
Robert Sauerwein
@nl
type
label
Robert Sauerwein
@en
Robert Sauerwein
@es
Robert Sauerwein
@nl
prefLabel
Robert Sauerwein
@en
Robert Sauerwein
@es
Robert Sauerwein
@nl